Answers are grounded in this paper and cite their sources.
Background Central nervous system (CNS) diseases remain therapeutic challenges due to complex pathology and poor drug penetration across the blood–brain barrier (BBB). Ginsenosides, the active components of Panax ginseng, possess multi-target neuroprotective properties but exhibit low bioavailability. Purpose This review synthesizes current evidence on ginsenoside mechanisms and evaluates the role of nanotechnology in enhancing their delivery and efficacy for CNS disorders. Study design A systematic search was conducted following PRISMA guidelines across PubMed, Web of Science, CNKI, and Google Scholar (2015–present). Included studies investigated ginsenosides in neurological disease models and nano-formulation strategies. Results Ginsenosides modulate neuroinflammation, oxidative stress, apoptosis, and calcium homeostasis through pathways involving NF-κB, Nrf2, and Bcl-2/Bax. Nano-delivery systems—such as liposomes, polymeric nanoparticles, and biomimetic vesicles—significantly improve ginsenoside stability, BBB traversal, and brain-targeted accumulation. Functionalization with ligands (e.g., Angiopep-2) or cell membranes further enhances specificity and therapeutic outcomes in ischemic stroke, glioma, Alzheimer’s disease, and spinal cord injury models. Conclusion Nanotechnology-based delivery systems potently augment the neuroprotective potential of ginsenosides, offering a promising strategy for multi-target CNS therapy. Future efforts should focus on translational safety, scalable production, and clinical validation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: